Meindert Danhof

Meindert Danhof

Auto-generated profile, based on publicly available information

Meindert Danhof

Leiden University

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2008 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
MDM Danhof
M Danhof
ELElizabeth De Lange
Elizabeth De Lange
ODO Dellapasqua
O Dellapasqua
BPB Ploeger
B Ploeger
RVR Voskuyl
R Voskuyl

1 February 2007 in Annual Review of Pharmacology and Toxicology
Verified
Journal Article
Closed access
MDMeindert Danhof
Meindert Danhof
JJJoost de Jongh
Joost de Jongh
ELElizabeth De Lange
Elizabeth De Lange
OPOscar Della Pasqua
Oscar Della Pasqua
BPBart A. Ploeger
Bart A. Ploeger
RVRob A. Voskuyl
Rob A. Voskuyl
Mechanism-based PK-PD models differ from conventional PK-PD models in that they contain specific expressions to characterize, in a quantitative manner, processes on the causal path between drug administration and effect. This includes target site distribution, target binding and activation, pharmacodynamic interactions, transduction, and homeostatic feedback mechanisms. As the final step, the effects on disease processes and disease progression are considered. Particularly through the incorporation of concepts from receptor theory and dynamical systems analysis, important progress has been made in the field of mechanism-based PK-PD modeling. This has yielded models with much-improved properties for extrapolation and prediction. These models constitute a theoretical basis for rational drug discovery and development.

16 January 2008 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Open access
PDF file
TPTeun M. Post
Teun M. Post
JFJan I. Freijer
Jan I. Freijer
BPBart A. Ploeger
Bart A. Ploeger
MDMeindert Danhof
Meindert Danhof
The Visual Predictive Check (VPC) is a valuable and supportive instrument for evaluating model performance. However in its most commonly applied form, the method largely depends on a subjective comparison of the distribution of the simulated data with the observed data, without explicitly quantifying and relating the information in both. In recent adaptations to the VPC this drawback is taken into consideration by presenting the observed and predicted data as percentiles. In addition, in some of these adaptations the uncertainty in the predictions is represented visually. However, it is not assessed whether the expected random distribution of the observations around the predicted median trend is realised in relation to the number of observations. Moreover the influence of and the information residing in missing data at each time point is not taken into consideration. Therefore, in this investigation the VPC is extended with two methods to support a less subjective and thereby more adequate evaluation of model performance: (i) the Quantified Visual Predictive Check (QVPC) and (ii) the Bootstrap Visual Predictive Check (BVPC). The QVPC presents the distribution of the observations as a percentage, thus regardless the density of the data, above and below the predicted median at each time point, while also visualising the percentage of unavailable data. The BVPC weighs the predicted median against the 5th, 50th and 95th percentiles resulting from a bootstrap of the observed data median at each time point, while accounting for the number and the theoretical position of unavailable data. The proposed extensions to the VPC are illustrated by a pharmacokinetic simulation example and applied to a pharmacodynamic disease progression example.

24 August 2005 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
MDMeindert Danhof
Meindert Danhof
GAGunnar Alvan
Gunnar Alvan
SDSvein G. Dahl
Svein G. Dahl
JKJochen Kuhlmann
Jochen Kuhlmann
GPGilles PAINTAUD
Gilles PAINTAUD

22 March 2006 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Closed access
PDF file
WWWillem de Winter
Willem de Winter
JDJoost DeJongh
Joost DeJongh
TPTeun Post
Teun Post
BPBart Ploeger
Bart Ploeger
RURichard Urquhart
Richard Urquhart
MDMeindert Danhof
Meindert Danhof

1 October 2016 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
MDMeindert Danhof
Meindert Danhof
Mechanism-based pharmacokinetic and pharmacodynamics (PKPD) and disease system (DS) models have been introduced in drug discovery and development research, to predict in a quantitative manner the effect of drug treatment in vivo in health and disease. This requires consideration of several fundamental properties of biological systems behavior including: hysteresis, non-linearity, variability, interdependency, convergence, resilience, and multi-stationarity. Classical physiology-based PKPD models consider linear transduction pathways, connecting processes on the causal path between drug administration and effect, as the basis of drug action. Depending on the drug and its biological target, such models may contain expressions to characterize i) the disposition and the target site distribution kinetics of the drug under investigation, ii) the kinetics of target binding and activation and iii) the kinetics of transduction. When connected to physiology-based DS models, PKPD models can characterize the effect on disease progression in a mechanistic manner. These models have been found useful to characterize hysteresis and non-linearity, yet they fail to explain the effects of the other fundamental properties of biological systems behavior. Recently systems pharmacology has been introduced as novel approach to predict in vivo drug effects, in which biological networks rather than single transduction pathways are considered as the basis of drug action and disease progression. These models contain expressions to characterize the functional interactions within a biological network. Such interactions are relevant when drugs act at multiple targets in the network or when homeostatic feedback mechanisms are operative. As a result systems pharmacology models are particularly useful to describe complex patterns of drug action (i.e. synergy, oscillatory behavior) and disease progression (i.e. episodic disorders). In this contribution it is shown how physiology-based PKPD and disease models can be extended to account for internal systems interactions. It is demonstrated how SP models can be used to predict the effects of multi-target interactions and of homeostatic feedback on the pharmacological response. In addition it is shown how DS models may be used to distinguish symptomatic from disease modifying effects and to predict the long term effects on disease progression, from short term biomarker responses. It is concluded that incorporation of expressions to describe the interactions in biological network analysis opens new avenues to the understanding of the effects of drug treatment on the fundamental aspects of biological systems behavior.